Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pocket-Sized MRI could spot strokes at bedside

NCT ID NCT07702968

Diagnosis Sponsor: Leiden University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study evaluates a portable, low-field MRI device (Hyperfine Swoop) for diagnosing stroke in people arriving at the emergency department with symptoms lasting less than 12 hours. Participants receive the low-field scan in addition to standard CT imaging. The goal is to see if this compact MRI can reliably detect ischemic and hemorrhagic strokes and stroke mimics, potentially enabling faster diagnosis at the bedside.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
low-field MRI scan (Hyperfine Swoop, 0.064 Tesla)
What this could lead to
If successful, portable low-field MRI could enable faster, bedside stroke diagnosis, especially in settings where standard MRI is unavailable.
What could go wrong
This is a small, early-stage study (80 participants) focused on feasibility and accuracy; the low-field MRI may not match the diagnostic power of standard imaging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients presenting to the emergency department of a tertiary academic hospital (LUMC) with suspected acute stroke (stroke code activation) within 12 hours of symptom onset. The study population includes patients with ischemic stroke (large vessel occlusion and lacunar), hemorrhagic stroke, and stroke mimics, reflecting real-world acute stroke diagnostics.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years * Presentation with suspected acute stroke (stroke code activation by ambulance paramedics) * Symptom onset \< 12 hours prior to presentation * Admission to the emergency department of the Leiden University Medical Center (LUMC) during office hours * Undergoing standard-of-care head CT imaging at the emergency department * Ability to provide informed consent (written or verbal in the acute setting, with deferred written consent if applicable) Exclusion Criteria: * Imminent death * Severe claustrophobia preventing MRI * Presence of MRI-incompatible implanted devices (e.g., pacemaker, cochlear implant, insulin pump) * Known intra-ocular metallic foreign body or intracranial metallic clip/device identified on admission CT * Pregnancy * Acute life-threatening or disabling condition requiring immediate intervention that precludes study procedures * Any study-related delay that could interfere with time-critical stroke treatments (intravenous thrombolysis or endovascular thrombectomy)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hemorrhagic stroke ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute stroke Mri imaging

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Leiden University Medical Center

    RECRUITING

    Leiden, South Holland, 2333ZA, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.